Clinical trials: pharmacological study
Short Bowel Syndrome
Proof of Concept Study in Patients With Short Bowel Syndrome
This is a Phase I/II. proof of concept, open label, two-dose, dose escalation study of NM-002 in adult patients with SBS who previously responded to exenatide.
- Trial name
- NCT04379856
- Testing
- NM-002
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- 9 Meters Biopharma, Inc.
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberous Sclerosis Complex-associated Refractory Seizures
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.
- Trial name
- EXIST-3 (NCT01713946)
- Testing
- RAD001, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 366 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Trial of TAS-114 in Combination With S-1
A Phase I, Open-Label, International, Multicenter, Non-Randomized, Dose-Escalating Safety, Tolerance and Pharmacokinetic Study of Oral Administration of TAS-114 in Combination with S-1 in a Twice Daily Schedule for 14 Days in…
- Trial name
- NCT02454062
- Testing
- TAS-114, S-1
- Where
- 5 sites in Belgium, France and 2 more
- Volunteers
- 120 people
- Sponsor
- Taiho Oncology, Inc.
Neoplasms
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
This study will investigate the drug-drug interactions (DDIs) between rucaparib and oral rosuvastatin (Arm A), and between rucaparib and oral ethinylestradiol and levonorgestrel (Arm B), with rucaparib as a perpetrator.
- Trial name
- NCT03954366
- Testing
- Rucaparib, Rosuvastatin, Oral Contraceptives
- Where
- 7 sites in Hungary, Poland and 1 more
- Volunteers
- 36 people
- Sponsor
- pharmaand GmbH
Type 2 Diabetes
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting…
- Trial name
- NCT01195662
- Testing
- Dapagliflozin
- Where
- 298 sites in United States, Australia and 14 more
- Volunteers
- 2,245 people
- Sponsor
- AstraZeneca
Schizophrenia
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered…
- Trial name
- PROSIPAL (NCT01081769)
- Testing
- paliperidone palmitate injection, oral antipsychotics
- Where
- 94 sites in Austria, Belgium and 23 more
- Volunteers
- 769 people
- Sponsor
- Janssen-Cilag International NV
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone.
- Trial name
- NCT00528879
- Testing
- Dapagliflozin, Metformin
- Where
- 75 sites in United States, Argentina and 3 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca
Immunoglobulin G4 Related Disease
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD).
- Trial name
- NCT04520451
- Testing
- rilzabrutinib, Glucocorticoids
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Pulmonary Arterial Hypertension
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial…
- Trial name
- NCT05343637
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- Where
- 3 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Respira Therapeutics, Inc.
Cancer
A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer
This study investigates the pharmacokinetics of YM155, identifies the metabolic profile of YM155 and evaluates the safety and tolerability of YM155 after a 3-hour infusion in patients with advanced cancer
- Trial name
- NCT01023386
- Testing
- YM155
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Astellas Pharma Inc
Gaucher Disease
Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease
The purpose of this study is to learn more about Gaucher disease. The information we collect from medical histories and a blood sample from people with Gaucher disease may help us pinpoint certain things that are different…
- Trial name
- NCT00351156
- Testing
- Blood sample
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amicus Therapeutics
Open Angle Glaucoma, Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
- Trial name
- NCT02129673
- Testing
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- ViSci Ltd.
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Rheumatoid Arthritis
A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling.
- Trial name
- NCT06418529
- Testing
- tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept
- Where
- United States
- Volunteers
- 21,340 people
- Sponsor
- Pfizer
Clinical Pharmacology
A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects
The objective of this clinical trial is to examine the clinical pharmacology properties of TAK-233 in healthy female subjects
- Trial name
- NCT02113020
- Testing
- TAK-233
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Takeda
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety in patients with cancer.
- Trial name
- NCT01611623
- Testing
- SNX-5422
- Volunteers
- 9 people
- Sponsor
- Esanex Inc.
Osteoarthritis, Hypertension
To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension
To assess the effect of naproxcinod vs. naproxen and ibuprofen on arterial blood pressure in patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-112 (NCT00662896)
- Testing
- naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid
- Where
- 57 sites in United States
- Volunteers
- 300 people
- Sponsor
- NicOx
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension
This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension.
- Trial name
- NCT00652496
- Testing
- Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Allergan